Omeros (OMER) Releases Earnings Results, Misses Estimates By $0.04 EPS

Share on StockTwits

Omeros (NASDAQ:OMER) issued its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.04), Fidelity Earnings reports. The firm had revenue of $4.61 million for the quarter, compared to analysts’ expectations of $3.07 million. During the same quarter in the prior year, the business earned ($0.16) EPS.

Shares of Omeros stock traded down $3.00 during trading on Friday, reaching $13.02. 5,656,225 shares of the company traded hands, compared to its average volume of 613,109. Omeros has a 1-year low of $8.36 and a 1-year high of $27.00. The company has a market capitalization of $793.47 million, a PE ratio of -16.48 and a beta of 3.79.

In related news, VP Marcia S. Kelbon sold 7,529 shares of the business’s stock in a transaction on Friday, August 31st. The shares were sold at an average price of $25.75, for a total transaction of $193,871.75. Following the transaction, the vice president now owns 227,645 shares in the company, valued at approximately $5,861,858.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 12.10% of the stock is owned by insiders.

A number of research analysts have recently issued reports on the stock. ValuEngine downgraded shares of Omeros from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research report on Wednesday, July 18th. Maxim Group restated a “buy” rating and issued a $32.00 price target on shares of Omeros in a research report on Friday. HC Wainwright set a $34.00 price target on shares of Omeros and gave the stock a “buy” rating in a research report on Tuesday, July 24th. Finally, Wedbush set a $20.00 price target on shares of Omeros and gave the stock a “hold” rating in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $27.56.

COPYRIGHT VIOLATION WARNING: “Omeros (OMER) Releases Earnings Results, Misses Estimates By $0.04 EPS” was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3929144/omeros-omer-releases-earnings-results-misses-estimates-by-0-04-eps.html.

About Omeros

Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company markets OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States.

Further Reading: Rule of 72

Earnings History for Omeros (NASDAQ:OMER)

Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

iShares MSCI Emerging Markets ETF  Holdings Cut by Keybank National Association OH
iShares MSCI Emerging Markets ETF Holdings Cut by Keybank National Association OH
National Asset Management Inc. Raises Stake in CME Group Inc
National Asset Management Inc. Raises Stake in CME Group Inc
Micron Technology, Inc.  Shares Sold by National Asset Management Inc.
Micron Technology, Inc. Shares Sold by National Asset Management Inc.
Broadcom Inc  Holdings Reduced by National Asset Management Inc.
Broadcom Inc Holdings Reduced by National Asset Management Inc.
iShares S&P 500 Growth ETF  Holdings Trimmed by National Asset Management Inc.
iShares S&P 500 Growth ETF Holdings Trimmed by National Asset Management Inc.
NTV Asset Management LLC Acquires 12,704 Shares of Medtronic PLC
NTV Asset Management LLC Acquires 12,704 Shares of Medtronic PLC


Leave a Reply

© 2006-2018 Ticker Report